Palisade Bio Inc Total Liabilities
Palisade Bio Inc total liabilities. Based on the latest financial reports, Palisade Bio Inc (PALI) has total liabilities worth $5.57 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PALI financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Palisade Bio Inc (2005–2025)
Total liabilities of Palisade Bio Inc from 2005 to 2025. This chart illustrates how Palisade Bio Inc's total liabilities have evolved over time, based on quarterly financial data.
Palisade Bio Inc Competitors by Total Liabilities
The table below lists competitors of Palisade Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Darwin Precisions Corp
TW:6120
|
Taiwan | NT$7.48 Billion |
|
Ginwa Enterprise Group Inc
SHG:600080
|
China | CN¥370.80 Million |
|
TuanChe ADR
NASDAQ:TC
|
USA | $40.60 Million |
|
Tata Steel (Thailand) Public Company Limited
BK:TSTH
|
Thailand | ฿2.96 Billion |
|
The Orissa Minerals Development Company Limited
NSE:ORISSAMINE
|
India | Rs546.38 Million |
|
Prodware
PA:ALPRO
|
France | €512.59 Million |
|
JS Corp
KO:194370
|
Korea | ₩1.28 Trillion |
|
Kumho Ind
KO:002990
|
Korea | ₩1.26 Trillion |
Liability Composition Analysis (2005–2025)
This chart breaks down Palisade Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Palisade Bio Inc balance sheet assets.
Liquidity & Leverage Metrics
Palisade Bio Inc Total Liabilities Ratios Explained
Palisade Bio Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 24.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Palisade Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Palisade Bio Inc (2005–2025)
The table below shows the annual total liabilities of Palisade Bio Inc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.96 Million | +46.52% |
| 2024-12-31 | $3.39 Million | +23.69% |
| 2023-12-31 | $2.74 Million | -16.60% |
| 2022-12-31 | $3.28 Million | -36.20% |
| 2021-12-31 | $5.15 Million | -49.13% |
| 2020-12-31 | $10.12 Million | +594.01% |
| 2019-12-31 | $1.46 Million | -10.83% |
| 2018-12-31 | $1.63 Million | -69.55% |
| 2017-12-31 | $5.37 Million | -52.37% |
| 2016-12-31 | $11.27 Million | +12.94% |
| 2015-12-31 | $9.98 Million | -17.67% |
| 2014-12-31 | $12.12 Million | +10.27% |
| 2013-12-31 | $11.00 Million | +518.60% |
| 2012-12-31 | $1.78 Million | -26.74% |
| 2011-12-31 | $2.43 Million | -11.35% |
| 2010-12-31 | $2.74 Million | -65.88% |
| 2009-12-31 | $8.02 Million | +533.97% |
| 2008-12-31 | $1.27 Million | +24.47% |
| 2007-12-31 | $1.02 Million | +167.30% |
| 2006-12-31 | $380.36K | -63.07% |
| 2005-12-31 | $1.03 Million | -- |
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibroste… Read more